SEP-225441 is a modified-release formulation of eszopiclone. In 2007, we initiated a proof-of-concept study for SEP-225441 and enrolled approximately 450 patients for the treatment of generalized anxiety disorder (GAD). In early 2009, we announced that this study did not meet the primary endpoint, which was reduction in symptoms of GAD. Sepracor is currently further analyzing this data to determine whether SEP-225441 warrants further clinical development.